GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » ROC %

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) ROC % : 8.76% (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Tianjin Pharmaceutical Da Ren Tang Group's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 8.76%.

As of today (2024-12-12), Tianjin Pharmaceutical Da Ren Tang Group's WACC % is 13.36%. Tianjin Pharmaceutical Da Ren Tang Group's ROC % is 14.30% (calculated using TTM income statement data). Tianjin Pharmaceutical Da Ren Tang Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Tianjin Pharmaceutical Da Ren Tang Group ROC % Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group ROC % Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.04 12.26 12.47 13.86 16.17

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.24 7.76 24.33 18.27 8.76

Tianjin Pharmaceutical Da Ren Tang Group ROC % Calculation

Tianjin Pharmaceutical Da Ren Tang Group's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=121.601 * ( 1 - 11.56% )/( (611.903 + 718.593)/ 2 )
=107.5439244/665.248
=16.17 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1456.887 - 431.523 - ( 413.461 - max(0, 478.138 - 1039.265+413.461))
=611.903

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1432.747 - 416.515 - ( 297.639 - max(0, 452.778 - 917.576+297.639))
=718.593

Tianjin Pharmaceutical Da Ren Tang Group's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=84.852 * ( 1 - 19.23% )/( (651.419 + 912.77)/ 2 )
=68.5349604/782.0945
=8.76 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1640.468 - 586.909 - ( 476.123 - max(0, 723.667 - 1125.807+476.123))
=651.419

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1550.244 - 431.901 - ( 205.573 - max(0, 592.415 - 1006.505+205.573))
=912.77

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Pharmaceutical Da Ren Tang Group  (SGX:T14) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tianjin Pharmaceutical Da Ren Tang Group's WACC % is 13.36%. Tianjin Pharmaceutical Da Ren Tang Group's ROC % is 14.30% (calculated using TTM income statement data). Tianjin Pharmaceutical Da Ren Tang Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tianjin Pharmaceutical Da Ren Tang Group ROC % Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group Headlines

No Headlines